Sparsha Pharma International Pvt. Was established in 2008 as the first transdermal company in India to engage in R&D, manufacturing and marketing of transdermal. The Hokunalin® Tape jointly developed in 1988 by Abbott Japan Co., Ltd and Nitto Denko was the world's first transdermal patch for treatment of asthma. Transdermal and Intravaginal Steroid Contraceptives. India ink colloidal carbon stain. India, in the Asian subcontinent is the world’s fourth largest. Where can I buy nicotine patches in India? Use of nicotine patches is not common in India. You can get 2baconil India's first nicotine transdermal patch on.

Chapter 1: World’s First Transdermal Patch for Treatment of Asthma The Hokunalin® Tape jointly developed in 1988 by Abbott Japan Co., Ltd and Nitto Denko was the world's first transdermal patch for treatment of asthma. The adhesive layer of the tape contains tulobuterol, a drug that dilates the bronchial tubes making it easier for asthma sufferers to breathe. When the patch is applied to the skin, the drug penetrates the skin and is absorbed into the blood stream through the capillaries to flow throughout the body. Sotn Full Screen Patch. This is in effect the same as using an injection, but without requiring the use of a needle. Unlike conventional oral and inhaled formulations, Hokunalin® Tape has the advantage of being able to appropriately control the concentration of the drug in the body. This means that users can control asthma attacks, which frequently occur in the early morning, and that the burden on caregivers is also greatly reduced. The development of these patches, however, took 11 years and was full of challenges.

The mechanism whereby drugs are delivered to the body through the transdermal patch. Designing transdermal patches is one area in which Nitto Denko has a great deal of expertise. By 1983 we had already developed a transdermal patch for preventing the onset of angina. With conventional transdermal formulations, drugs were continuously in the body for long periods of time. The developers wanted to develop a more advanced product that was able to deliver the required drug dosage at the right time for use in the treatment of asthma. In many cases, asthma attacks occur at set times, such as in the early morning.

If a drug delivery system could be developed that was able to deliver the optimum amount of medication at that time (a smart drug delivery system), then it would be possible to dramatically increase the quality of life of asthma sufferers. In order to realize this goal, however, it is necessary to achieve precision control of drug release speed. This proved to be extremely difficult. Chapter 3: Tenacity was required to Solve the Problem of Drug Content and Concentration Control Drug release speed is determined by the complex relationships between the type of adhesive used, the thickness of the adhesive coating, and the content and concentration of drug contained in the adhesive. Moreover, the type of adhesive that can be used in medical applications is also limited, which means that inevitably it is necessary to control release speed using drug content and concentration. In the absence of any revolutionary way of solving this problem, it was a matter of making samples with various combinations in a process of trial and error.

Although computer simulations can now be used for parts of this process, at that particular time there was no such convenience. It was a case of trying every combination and investigating each individual possibility. Eventually, as a result of many years of painstaking hard work, this goal was achieved by utilizing a mechanism whereby some of the drug in the adhesive was maintained in a crystalline state while the rest was kept in a dissolved state.